Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

Cancer Cell

Volumn 28, Issue 1, 2015, Pages 29-41

  Wu, Shuo Chieh ^a   Li, Loretta S ^a   Kopp, Nadja ^a   Montero, Joan ^a   Chapuy, Bjoern ^a   Yoda, Akinori ^a   Christie, Amanda L ^a   Liu, Huiyun ^a   Christodoulou, Alexandra ^a   vanBodegom, Diederik ^a   vanderZwet, Jordy ^a   Layer, Jacob V ^a   Tivey, Trevor ^a   Lane, Andrew A ^a   Ryan, Jeremy A ^a   Ng, Samuel Y ^a   DeAngelo, Daniel J ^a   Stone, Richard M ^a   Steensma, David ^a   Wadleigh, Martha ^a   Harris, Marian ^a   Mandon, Emeline ^b   Ebel, Nicolas ^b   Andraos, Rita ^b   Romanet, Vincent ^b   Dölemeyer, Arno ^b   Sterker, Dario ^b   Zender, Michael ^b   Rodig, Scott J ^c   Murakami, Masato ^b   Hofmann, Francesco ^b   Kuo, Frank ^c   Eck, Michael J ^a   Silverman, Lewis B ^a   Sallan, Stephen E ^a   Letai, Anthony ^a   Baffert, Fabienne ^b   Vangrevelinghe, Eric ^b   Radimerski, Thomas ^b   Gaul, Christoph ^b   Weinstock, DavidM ^a,d   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHZ 868; DEXAMETHASONE; JANUS KINASE INHIBITOR; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CHZ868; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROTECTION; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR CELL LINE;

MURINAE; MUS;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZIMIDAZOLES; CELL LINE, TUMOR; CYTOPROTECTION; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; JANUS KINASE 2; MICE; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937395764     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.06.005     Document Type: Article

References (37)

1. Akada H., Akada S., Hutchison R.E., Sakamoto K., Wagner K.U., Mohi G. Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells. Stem Cells 2014, 32:1878-1889.
2. Andraos R., Qian Z., Bonenfant D., Rubert J., Vangrevelinghe E., Scheufler C., Marque F., Regnier C.H., De Pover A., Ryckelynck H., et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Disc. 2012, 2:512-523.
3. Ausserlechner M.J., Obexer P., Böck G., Geley S., Kofler R. Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells. Cell Death Differ. 2004, 11:165-174.
4. Azam M., Latek R.R., Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003, 112:831-843.
5. Baffert F., Régnier C.H., De Pover A., Pissot-Soldermann C., Tavares G.A., Blasco F., Brueggen J., Chène P., Drueckes P., Erdmann D., et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol. Cancer Ther. 2010, 9:1945-1955.
6. Cesarman E. Pathology of lymphoma in HIV. Curr. Opin. Oncol. 2013, 25:487-494.
7. Foà R., Vitale A., Vignetti M., Meloni G., Guarini A., De Propris M.S., Elia L., Paoloni F., Fazi P., Cimino G., et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011, 118:6521-6528. GIMEMA Acute Leukemia Working Party.
8. He M., Capelletti M., Nafa K., Yun C.H., Arcila M.E., Miller V.A., Ginsberg M.S., Zhao B., Kris M.G., Eck M.J., et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin. Cancer Res. 2012, 18:1790-1797.
9. Hertzberg L., Vendramini E., Ganmore I., Cazzaniga G., Schmitz M., Chalker J., Shiloh R., Iacobucci I., Shochat C., Zeligson S., et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115:1006-1017.
10. Jing D., Bhadri V.A., Beck D., Thoms J.A., Yakob N.A., Wong J.W., Knezevic K., Pimanda J.E., Lock R.B. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood 2015, 125:273-283.
11. Koppikar P., Bhagwat N., Kilpivaara O., Manshouri T., Adli M., Hricik T., Liu F., Saunders L.M., Mullally A., Abdel-Wahab O., et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012, 489:155-159.
12. Lane A.A., Chapuy B., Lin C.Y., Tivey T., Li H., Townsend E.C., van Bodegom D., Day T.A., Wu S.C., Liu H., et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat. Genet. 2014, 46:618-623.
13. Maude S.L., Tasian S.K., Vincent T., Hall J.W., Sheen C., Roberts K.G., Seif A.E., Barrett D.M., Chen I.M., Collins J.R., et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2012, 120:3510-3518.
14. Mesbah K., Rana M.S., Francou A., van Duijvenboden K., Papaioannou V.E., Moorman A.F., Kelly R.G., Christoffels V.M. Identification of a Tbx1/Tbx2/Tbx3 genetic pathway governing pharyngeal and arterial pole morphogenesis. Hum. Mol. Genet. 2012, 21:1217-1229.
15. Meyer S.C., Keller M.D., Chiu S., Koppikar P., Guryanova O.A., Rapaport F., Xu K., Manova K., Pankov D., O'Reilly R.J., et al. CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms. Cancer Cell 2015, 28:15-28. this issue.
16. Montero J., Sarosiek K.A., DeAngelo J.D., Maertens O., Ryan J., Ercan D., Piao H., Horowitz N.S., Berkowitz R.S., Matulonis U., et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 2015, 160:977-989.
17. Monti S., Chapuy B., Takeyama K., Rodig S.J., Hao Y., Yeda K.T., Inguilizian H., Mermel C., Currie T., Dogan A., et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell 2012, 22:359-372.
18. Morse H.C., Anver M.R., Fredrickson T.N., Haines D.C., Harris A.W., Harris N.L., Jaffe E.S., Kogan S.C., MacLennan I.C., Pattengale P.K., Ward J.M. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 2002, 100:246-258. Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium.
19. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., Loudin M.G., Liu W., Zhang J., Ma J., Coustan-Smith E., Harvey R.C., Willman C.L., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat. Genet. 2009, 41:1243-1246.
20. Mullighan C.G., Zhang J., Harvey R.C., Collins-Underwood J.R., Schulman B.A., Phillips L.A., Tasian S.K., Loh M.L., Su X., Liu W., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 2009, 106:9414-9418.
21. Pan R., Hogdal L.J., Benito J.M., Bucci D., Han L., Borthakur G., Cortes J., DeAngelo D.J., Debose L., Mu H., et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014, 4:362-375.
22. Park S.O., Wamsley H.L., Bae K., Hu Z., Li X., Choe S.W., Slayton W.B., Oh S.P., Wagner K.U., Sayeski P.P. Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PLoS ONE 2013, 8:e59675.
23. Pui C.H., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. N.Engl. J. Med. 2004, 350:1535-1548.
24. Rhee K., Bresnahan W., Hirai A., Hirai M., Thompson E.A. c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation. Cancer Res. 1995, 55:4188-4195.
25. Roberts K.G., Morin R.D., Zhang J., Hirst M., Zhao Y., Su X., Chen S.C., Payne-Turner D., Churchman M.L., Harvey R.C., et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012, 22:153-166.
26. Roberts K.G., Li Y., Payne-Turner D., Harvey R.C., Yang Y.L., Pei D., McCastlain K., Ding L., Lu C., Song G., et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N.Engl. J. Med. 2014, 371:1005-1015.
27. Russell L.J., Capasso M., Vater I., Akasaka T., Bernard O.A., Calasanz M.J., Chandrasekaran T., Chapiro E., Gesk S., Griffiths M., et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114:2688-2698.
28. Sessa C., Shapiro G.I., Bhalla K.N., Britten C., Jacks K.S., Mita M., Papadimitrakopoulou V., Pluard T., Samuel T.A., Akimov M., et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin. Cancer Res. 2013, 19:3671-3680.
29. Shiels M.S., Pfeiffer R.M., Gail M.H., Hall H.I., Li J., Chaturvedi A.K., Bhatia K., Uldrick T.S., Yarchoan R., Goedert J.J., Engels E.A. Cancer burden in the HIV-infected population in the United States. J.Natl. Cancer Inst. 2011, 103:753-762.
30. Shochat C., Tal N., Bandapalli O.R., Palmi C., Ganmore I., te Kronnie G., Cario G., Cazzaniga G., Kulozik A.E., Stanulla M., et al. Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J.Exp. Med. 2011, 208:901-908.
31. Shochat C., Tal N., Gryshkova V., Birger Y., Bandapalli O.R., Cazzaniga G., Gershman N., Kulozik A.E., Biondi A., Mansour M.R., et al. Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood 2014, 124:106-110.
32. Tasian S.K., Doral M.Y., Borowitz M.J., Wood B.L., Chen I.M., Harvey R.C., Gastier-Foster J.M., Willman C.L., Hunger S.P., Mullighan C.G., Loh M.L. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood 2012, 120:833-842.
33. Waibel M., Solomon V.S., Knight D.A., Ralli R.A., Kim S.K., Banks K.M., Vidacs E., Virely C., Sia K.C., Bracken L.S., et al. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep. 2013, 5:1047-1059.
34. Watanabe S., Itoh T., Arai K. JAK2 is essential for activation of c-fos and c-myc promoters and cell proliferation through the human granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells. J.Biol. Chem. 1996, 271:12681-12686.
35. Weigert O., Lane A.A., Bird L., Kopp N., Chapuy B., van Bodegom D., Toms A.V., Marubayashi S., Christie A.L., McKeown M., et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J.Exp. Med. 2012, 209:259-273.
36. Wohlmann A., Sebastian K., Borowski A., Krause S., Friedrich K. Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function. Biol. Chem. 2010, 391:181-186.
37. Yoda A., Yoda Y., Chiaretti S., Bar-Natan M., Mani K., Rodig S.J., West N., Xiao Y., Brown J.R., Mitsiades C., et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 2010, 107:252-257.